Please Wait...

Patient Engagement in Alzheimer's and Mild Cognitive Impairment Clinical Trials

Considering the large number of individuals affected by Alzheimer's disease (AD) or Mild Cognitive Impairment (MCI), you might expect fast enrollment into clinical trials. The reality is quite different. Sponsors of clinical trials face several obstacles: 1) Patients are underdiagnosed. 2) Patients have a limited knowledge of clinical trials and some misconceptions. 3) AD/MCI clinical trials are complex, prohibiting participation.

The fastest and easiest solution is to educate people online. However, many of the individuals affected by AD/MCI do not have sophisticated digital media and computer experience. In situations where people have been diagnosed with AD, their children often navigate online for answers. And when it comes to recruiting participants for MCI trials, younger family members might not even be aware that their parent has memory problems. Therefore, although an online presence is necessary and can certainly improve overall awareness and dialogue inside families, it is insufficient to overcome all the obstacles impeding involvement in AD/MCI clinical trials.

At Bioclinica, we have diversified and adapted our engagement strategies to better reach people with AD/MCI, including:

  • Developing a large community outreach effort that offers services such as educational seminars, free memory testing, and genetic testing.
  • Advertising events in the newspapers, on the radio, or through local AD community actors.
  • Giving event participants an opportunity to ask questions of a doctor.

Community events dedicated to providing education on memory loss had the most success. Patient engagement increased when those events were coupled with the opportunity to undergo a memory test or genetic testing. Out of 75 AD/MCI patients screened in clinical trials within one month, 21% originated from community events, 38% from referrals, 21% from our database, and 11% from digital media and online efforts.

Diversity in approach is the key to getting past the obstacles associated with AD/MCI clinical trials. Testing different advertising methods and event formats, foci, and services is crucial to gaining the patient engagement sponsors desire.

Learn more about Bioclinica's capabilities and experience in Alzheimer's disease research and patient engagement.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

RT @scrtrials: Sam Shepard's passing is a reminder of the fight against ALS. 2016 was an important year for discovery. https://t.co/LP5nw0m…
bioclinica (4 days ago)
RT @eClinical_Jen: SCDM White Papers on Mobile Health and eSource by the Leading Data Managment Organization https://t.co/1cG50Lqvj2 #eheal…
bioclinica (5 days ago)
RT @eClinical_Jen: Data Managers - There is a FREE guideline for Good Clinical Data Management Practices here: https://t.co/4g7kF6aGGA #ehe…
bioclinica (5 days ago)
RT @Xtalks: IRT Best Practices: How Companies are Accelerating Timelines While Improving Quality Live webinar with @bioclinica https://t.co…
bioclinica (5 days ago)
Cardiovascular imaging use is growing in non-cardiovascular areas #ClinicalTrials. See where in Tim Crowe's blog… https://t.co/7LvcKCds28
bioclinica (5 days ago)
A quick primer on analyzing risk in business processes by our Director of RTSM Delivery Nick Hargaden https://t.co/WOxLTqCvEk
bioclinica (5 days ago)

Latest Blogs: